Navigation Links
Study shows over 200 mobile apps related to dermatology
Date:9/26/2013

AURORA, Colo. (Sept. 25, 2013) A surge of mobile apps related to dermatology has allowed scores of smart phone users to track and diagnose a wide range of skin diseases but doctors are urging caution, according to a study published today in the Journal of the American Medical Association.

"There are 229 dermatological applications out there and most are free," said Robert Dellavalle, MD, PhD, MSPH, senior author of the study and Associate Professor of Dermatology at the University of Colorado School of Medicine. "Yet this is an area of buyer beware because there are no regulations and no guarantees that these apps are providing accurate medical information."

The study found mobile applications for monitoring psoriasis, connecting people with patient organizations, diagnosing melanoma, dispensing sun screen advice, dermatology education and skin medications.

Self-surveillance/diagnosis apps vary widely in capabilities. Some allow patients to document lesions, upload and receive dermatologist or algorithm-based feedback about the malignancy potential of lesions, follow diagnosis algorithms and log personal treatment regimens.

Others are focused on a single malady like acne, rosacea, psoriasis or eczema. Patients and doctors can interface on apps and one lets users get pathology results from their phone. Another, Dr. Mole, allows users to photograph a mole and monitor its changes over time to determine if it's cancerous.

The 10 most reviewed apps included:

    1. Ultraviolet-UV Index
    2. VisualDx
    3. SPF
    4. iSore
    5. SpotMole
    6. Pocket Derm
    7. Skin Scan
    8. Doctor Mole
    9. What's My Rash?
    10. Skin Conditions

The U.S. Food and Drug Administration announced Monday that it would only regulate the small number of apps that act like medical instruments, those that perform ultrasounds or other procedures.

Dellavalle, Chief of Dermatology at the Denver Veterans Affairs Medical Center, said the rise in medical apps in general and dermatology in particular offers the chance to expand care into rural and underserved populations.

They may also help mitigate the shortage of dermatologists nationwide. Still, he urged people to use common sense.

"There is a huge expansion of medical apps across all disciplines now. This will require some caution by users but it also opens up new opportunities," he said. "I think most apps are generally safe right now, but I would not rely solely on them. I would cross-reference them with other apps, other people and with your doctor."


'/>"/>

Contact: David Kelly
david.kelly@ucdenver.edu
303-503-7990
University of Colorado Denver
Source:Eurekalert

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... , Feb. 16, 2017   Biostage, Inc. ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, announced today the closing on February ... 20,000,000 shares of common stock and warrants to purchase ... of $8.0 million. The offering was priced at $0.40 ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... Series 1a financing and entered into a $5 ...  Dermata intends to use the capital for general ... major advancements in the treatment of serious diseases ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
Breaking Biology Technology:
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):